Slower-than-expected progression of hepatic fibrosis resulted in the trial being stopped early.
During the past decade, several clinical trials have been initiated to explore whether maintenance interferon might slow the progression of hepatic fibrosis in individuals who do not respond to hepatitis C virus (HCV) therapy. To date, results have been published for two of these trials: HALT-C, which showed no benefit among HCV-monoinfected patients (JW Infect Dis Dec 10 2008), and now SLAM-C, which involved HIV/HCV-coinfected patients.
In this trial, HIV/HCV-coinfected patients with fibrosis of at least stage 1 on liver biopsy were treated with peginterferon alfa-2a plus ribavirin. At week 12, patients who did not have an early virologic response (EVR; defined as clearance of — or at least a 2-log drop in — HCV RNA) were randomized to rece…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)